A previously healthy 37-year-old woman was diagnosed with superficial spreading melanoma (tumor thickness 14.8 mm, CL IV-V) in the left posterior shoulder (stage IIIc, pT4a pN2c cM0). After both interferonalpha (IFNα) therapy and subsequently initiated dacarbazine (DTIC) chemotherapy, restaging indicated progressive disease with newly developed lymph node, soft tissue, and bone metastasis (stage IV, pT4a pN3 M1c). Hence, a therapy with ipilimumab was initiated. This led to a significant decrease of the tumor marker s-100 to a normal level. After four cycles of ipilimumab, vital tumor tissue could not be detected via [ 18 F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), thus the imaging substantiated a complete remission of the disease. The follow-up every 4 months for a total of 1 year confirmed the therapeutic success.
Our study demonstrates a response monitoring via FDG-PET/CT before and after a therapy of ipilimumab in a patient with refractory metastatic melanoma [ Figure 1 ]. Ipilimumab (YERVOY) is a monoclonal antibody that mobilizes the T-cell-immune response and thus exerts an anti-tumorimmunogenic effect. [1] [2] [3] It blocks CTLA-4,
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3). (d) The last image is FDG-PET/CT after ipilimumab-therapy (IPI).
There was no evidence of vital, FDG-positive tumor tissue. Thus, in comparison to the previous study, there was a significant improvement of the known osseous (d1) and lymphatic metastatic spread.
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which is expressed on T cells and slows down the immune response. [4, 5] The effects of ipilimumab are induced by the excessive activity of the immune system. [1] [2] [3] [4] This substance proved to be effective in advanced melanoma and showed a significant improvement of the overall survival. [1] [2] [3] FDG-PET/CT is highly sensitive in detecting sites of disease; therefore, it has an established role in the managing of metastatic melanoma. [6, 7] Sachpekidis et al. [8] show that FDG-PET/CT has a good predictive efficiency of the final treatment outcome after therapy with ipilimumab in patients with metastatic melanoma.
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